Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?

被引：0

作者：

Boisdron-Celle, Michele ^{[1
]}

机构：

[1] INSERM, CRCNA, Inst Cancerol Ouest,U892,Dept Biopathol Cancer, Unite Oncopharmacol & Pharmacogenet, F-49988 Angers 9, France

来源：

PHARMACOGENOMICS | 2012年 / 13卷 / 13期

关键词：

5-FU; colorectal cancer; dose adjustment; fluoropyrimidines; personalized medicine; pharmacokinetic; PK; TDM; toxicity; METASTATIC COLORECTAL-CANCER; CONTINUOUS-INFUSION; RANDOMIZED-TRIAL; NECK-CANCER; FLUOROURACIL; 5-FU; PLASMA; LEUCOVORIN; DOSAGE; HEAD;

D O I：

10.2217/PGS.12.132

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1437 / 1439

页数：3

共 16 条

[1] EFFECT OF PLYOMETRIC TRAINING ON SWIMMING BLOCK START PERFORMANCE IN ADOLESCENTS [J].

Bishop, Daniel C. ;

Smith, Russell J. ;

Smith, Mark F. ;

Rigby, Hannah E. .

JOURNAL OF STRENGTH AND CONDITIONING RESEARCH, 2009, 23 (07) :2137-2143

[2]

Capitain O, 2010, 2010 GASTR CANC S OR

[3] Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study [J].

Capitain, Olivier ;

Asevoaia, Andreaa ;

Boisdron-Celle, Michele ;

Poirier, Anne-Lise ;

Morel, Alain ;

Gamelin, Erick .

CLINICAL COLORECTAL CANCER, 2012, 11 (04) :263-267

[4] Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study [J].

deGramont, A ;

Basset, JF ;

Milan, C ;

Rougier, P ;

Bouche, O ;

Etienne, PL ;

Morvan, F ;

Louvet, C ;

Guillot, C ;

Francois, E ;

Bedenne, L .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :808-815

[5] Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma [J].

Gamelin, E ;

BoisdronCelle, M ;

Turcant, A ;

Larra, F ;

Allain, P ;

Robert, J .

JOURNAL OF CHROMATOGRAPHY B, 1997, 695 (02) :409-416

[6] Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin:: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients [J].

Gamelin, É ;

Boisdron-Celle, M ;

Delva, R ;

Regimbeau, C ;

Cailleux, PE ;

Alleaume, C ;

Maillet, ML ;

Goudier, MJ ;

Sire, M ;

Person-Joly, MC ;

Maigre, M ;

Maillart, P ;

Fety, R ;

Burtin, P ;

Lortholary, A ;

Dumesnil, Y ;

Picon, L ;

Geslin, J ;

Gesta, P ;

Danquechin-Dorval, E ;

Larra, F ;

Robert, J .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1470-1478

[7]

Gamelin EC, 1996, CANCER, V77, P441, DOI 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO

[8]

2-N

[9] Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer [J].

Gamelin, Erick ;

Delva, Remy ;

Jacob, Jacques ;

Merrouche, Yacine ;

Raoul, Jean Luc ;

Pezet, Denis ;

Dorval, Etienne ;

Piot, Gilles ;

Morel, Alain ;

Boisdron-Celle, Michele .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2099-2105

[10] CLINICAL RESPONSE AND PLASMA-LEVELS OF 5-FLUOROURACIL IN PATIENTS WITH COLONIC CANCER TREATED BY DRUG INFUSION [J].

HILLCOAT, BL ;

MCCULLOCH, PB ;

FIGUEREDO, AT ;

EHSAN, MH ;

ROSENFELD, JM .

BRITISH JOURNAL OF CANCER, 1978, 38 (06) :719-724

← 1 2 →